Clinical Trial

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma, aiming to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of JMT108 Injection in this population. The study consists of Phase I and Phase II (including Phase IIa and Phase IIb), where Phase I is the dose-escalation stage, Phase IIa is the dose-expansion stage, and Phase IIb is the cohort-expansion stage.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-10.
Status change: Not Yet Recruiting → Recruiting 2026-01-06
Trial Details
NCT Number NCT07280832
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Unresectable Locally Advanced or Metastatic Melanoma
Enrollment 188 participants
Start Date 2025-12-17
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-07